Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 214

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 214
---
 limitation of 4.99%, which does not permit selling         
 shareholder to exercise that portion of the warrants that would result in the selling shareholder and its affiliates owning, after         
 exercise, a number of common shares in excess of the beneficial ownership limitation. The amounts and percentages in the table do          
 not give effect to the 4.99% beneficial ownership limitation.                                                                              |
| (37) | Consists of (i) 13,980 common shares issuable upon                                                                                         
 the exercise of warrants previously issued and (ii) 13,980 common shares issuable upon the exercise of the Additional Warrant Shares       
 underlying the January 2024 PIPE Warrants.                                                                                                 |
| (38) | Consists of 13,980 common shares issuable upon the                                                                                         
 exercise of the Additional Warrant Shares underlying the January 2024 PIPE Warrants.                                                       |
| (39) | Consists of 13,980 common shares issuable upon the                                                                                         
 exercise of previously issued warrants.                                                                                                    |

139 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS The following is a description of the material terms of those transactions with related parties to which we, or our subsidiaries, are party. Cooperation Agreement with SciSparc Ltd. On March 7, 2022, we entered into a cooperation agreement with SciSparc, pursuant to which we will explore with SciSparc the scientific and commercial potential for creating pharmaceutical solutions for several indications including CNS related indications. Under such agreement, the companies are exploring a combined molecule that the parties have created that is undergoing a joint pre-clinical study. To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they will enter into a joint venture where the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture and the development of the molecule remains in a very early stage. Adi Zuloff-Shani, our Chief Executive Officer, serves as SciSparc’s Chief Technologies Officer; Amitay Weiss, the Chairman of our Board of Directors, serves as the Chairman of the Board of Directors of SciSparc; and Oz Adler, one of our directors, serves as the Chief Executive Officer and Chief Financial Officer of SciSparc. In June 2023, we announced that, as part of our ongoing collaboration with SciSparc, we entered into a research agreement